Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticoagulation and the GP patient

J V Lloyd1, S E Rodgers

  • 1Transfusion/Haemostasis Unit, Institute of Medical and Veterinary Science, Adelaide, South Australia.

Australian Family Physician
|August 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

M1761K mutation in the von Willebrand factor A3 domain associated with impaired collagen binding and without platelet dysfunction.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Effects of an air pollution personal alert system on health service usage in a high-risk general population: a quasi-experimental study using linked data.

Journal of epidemiology and community health·2016
Same author

Direct mutation analysis as the preferred method for carrier diagnosis in families with isolated cases of haemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.

British journal of cancer·2012
Same author

Hereditary disorders of platelet function.

Platelets·2010
Same author

New approaches in the measurement of coagulation.

Haemophilia : the official journal of the World Federation of Hemophilia·2008
Same journal

Occupational violence and staff safety in general practice.

Australian family physician·2018
Same journal

You should get that mole checked out: Ethical and legal considerations of the unsolicited clinical opinion.

Australian family physician·2018
Same journal

Understanding the decision to commence a dose administration aid.

Australian family physician·2018
Same journal

Psychological distress and risky sexual behaviours among women aged 16-25 years in Victoria, Australia.

Australian family physician·2018
Same journal

A mixed-methods feasibility study of routinely weighing patients in general practice to aid weight management.

Australian family physician·2018
Same journal

The Australian Mid-West Coastal Marine Wound Infections Study.

Australian family physician·2018
See all related articles

Understanding anticoagulant drugs like warfarin, heparin, and aspirin is crucial. This article highlights their distinct pharmacology and mechanisms of action for safe and effective use.

Area of Science:

  • Pharmacology
  • Drug Mechanisms
  • Anticoagulation Therapy

Background:

  • Anticoagulant medications are vital in preventing and treating thromboembolic disorders.
  • Effective use necessitates a thorough understanding of their pharmacological profiles.
  • Variations in drug action can significantly impact patient outcomes.

Purpose of the Study:

  • To elucidate the key pharmacological differences between commonly used anticoagulant drugs.
  • To compare the distinct mechanisms of action for warfarin, heparin, and aspirin.
  • To provide essential knowledge for healthcare professionals managing anticoagulant therapy.

Main Methods:

  • Comparative analysis of established pharmacological data.
  • Review of scientific literature on warfarin, heparin, and aspirin.

Related Experiment Videos

  • Focus on mechanisms of action and clinical applications.

    • Main Results:

    • Warfarin exhibits a distinct mechanism involving vitamin K antagonism.
    • Heparin functions through potentiation of antithrombin.
    • Aspirin, an antiplatelet agent, inhibits cyclooxygenase activity.

    Conclusions:

    • Significant pharmacological and mechanistic disparities exist among warfarin, heparin, and aspirin.
    • Tailoring anticoagulant therapy requires specific knowledge of each drug's profile.
    • Awareness of these differences is critical for optimizing patient safety and therapeutic efficacy.